-
Jun Lu1,2,3,4，Tianqing Chu1，Hongyu Liu1，Minjuan Hu1，Yuqing Lou1，Yanwei Zhang1，Zhiqiang Gao1，Wei Zhang1，Xueyan Zhang1，Huimin Wang1，Hua Zhong1，Baohui Han1,2,3（Department of Pulmonary Medicine Shanghai Chest Hospital Shanghai Jiao Tong University；Shanghai Institute of Thoracic Oncology Shanghai Chest Hospital Shanghai Jiao Tong University；Translational Medical Research Platform for Thoracic Oncology Shanghai Chest Hospital Shanghai Jiao Tong University；Department of Bio-bank Shanghai Chest Hospital Shanghai Jiao Tong University）.Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update[J].Chinese Journal of Cancer Research,2022,第1期
-
Zichen Zhao1，Jin Gu2,3,4,5（Peking University Wujieping Urology Center Peking University Shougang Hospital；Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Center of Gastrointestinal Cancer Peking University Cancer Hospital & Institute；Peking-Tsinghua Center for Life Science Peking University International Cancer Center；Department of Gastrointestinal Surgery Peking University Shougang Hospital；Center for Precision Diagnosis and Treatment of Colorectal Cancer and Inflammatory Diseases）.Open surgery in the era of minimally invasive surgery[J].Chinese Journal of Cancer Research,2022,第1期
-
Shichao Guo1，Guangchao Wang1，Zitong Zhao1，Dan Li1，Yongmei Song1，Qimin Zhan1,2（State Key Laboratory of Molecular Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College；Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Laboratory of Molecular Oncology Peking University Cancer Hospital & Institute）.Deregulated expression and subcellular localization of CPSF6, a circRNA-binding protein, promote malignant development of esophageal squamous cell carcinoma[J].Chinese Journal of Cancer Research,2022,第1期
-
Dongdong Ti，Xin Yan，Jianshu Wei，Zhiqiang Wu，Yao Wang，Weidong Han（Department of Bio-therapeutic the First Medical Center Chinese PLA General Hospital）.Inducing immunogenic cell death in immuno-oncological therapies[J].Chinese Journal of Cancer Research,2022,第1期
-
Yanqi Huang1,2,3，Lan He2，Zhenhui Li2,4，Xin Chen5，Chu Han2，Ke Zhao2，Yuan Zhang2，Jinrong Qu6，Yun Mao7，Changhong Liang1,2，Zaiyi Liu1,2,3（The Second School of Clinical Medicine Southern Medical University；Department of Radiology Guangdong Provincial People’s Hospital Guangdong Academy of Medical Sciences；Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application Guangdong Provincial People’s Hospital Guangdong Academy of Medical Sciences；Department of Radiology the Third Affiliated Hospital of Kunming Medical University Yunnan Cancer Hospital Yunnan Cancer Center；Department of Radiology Guangzhou First People’s Hospital School of MedicineSouth China University of Technology；Department of Radiology the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital；Department of Radiology the First Affiliated Hospital of Chongqing Medical University）.Coupling radiomics analysis of CT image with diversification of tumor ecosystem: A new insight to overall survival in stage I-III colorectal cancer[J].Chinese Journal of Cancer Research,2022,第1期
-
Zhitao Ying1，Ting He2，Shanzhao Jin2，Xiaopei Wang1，Wen Zheng1，Ningjing Lin1，Meifeng Tu1，Yan Xie1，Lingyan Ping1，Weiping Liu1，Lijuan Deng1，Yanping Ding2，Xuelian Hu2，Bing Bu3，Xin'an Lu2，Yuqin Song1，Jun Zhu1（Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Department of Lymphoma Peking University Cancer Hospital & Institute；Beijing Immunochina Pharmaceuticals Co. Ltd.；Department of Medical Oncology Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences）.A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma[J].Chinese Journal of Cancer Research,2022,第1期
|